Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Drugs - Ramatroban  Jan 03, 2022  2 years, 3 months, 2 weeks, 22 hours, 23 minutes ago

Study Shows Ramatroban, A Thromboxane A2 & Prostaglandin D2 Receptor Antagonist Can Be Used To Treat COVID Respiratory Distress And Hypoxemia

Study Shows Ramatroban, A Thromboxane A2 & Prostaglandin D2 Receptor Antagonist Can Be Used To Treat COVID Respiratory Distress And Hypoxemia
Source: COVID-19 Drugs - Ramatroban  Jan 03, 2022  2 years, 3 months, 2 weeks, 22 hours, 23 minutes ago
COVID-19 Drugs: A small clinical study conducted by researchers from the Charak Foundation-California-USA, Regulatory Wisdom-India, the EyeSight Eye Hospital and Retina Centre-India and the University of California Irvine-USA has found that the drug Ramatroban, which is a thromboxane A2 & prostaglandin D2 receptor antagonist can be used to treat COVID respiratory distress and hypoxemia.


 
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.researchsquare.com/article/rs-474882/v6

Please have a heart and help to support and sustain this website and all our research and community initiatives by making a donation. You help truly means a lot and helps saves lives directly and indirectly. Thank You.
https://www.thailandmedical.news/p/sponsorship


Hypoxemia or below-normal level of oxygen in the blood, often accompanying COVID-19 related pneumonia is dispositive for hospitalization and mechanical ventilation and contributes to increased risk of mortality. Other than oxygen supplementation, there is no treatment that resolves hypoxemia in COVID-19 pneumonia.
 
In May 2020, the Indian drug regulatory body, DCGI granted emergency approval for the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad, as an adjuvant drug to treat hospitalized COVID-19 patients and also to reduce supplemental oxygen dependence. It was reported that their Phase III clinical trial results showed that this molecule helps in COVID-19 hypoxemia and also faster recovery of hospitalized patients and reduces supplemental oxygen dependence. https://www.thailandmedical.news/news/breaking-india-approves-2-deoxy-d-glucose-2-dg-as-an-adjuvant-to-treat-covid-19-patients-and-reduce-supplemental-oxygen-dependence
 
However subsequently findings showed that the Indian study was just another typical substandard clinical trial the country was famous for and the drug did not really have any benefits.
 
In this new COVID-19 Drugs study, it was found that COVID-19 pneumonia sustains a massive increase in lipid mediators, especially thromboxane A2 >> PGE2 > PGD2.
 
Thromboxane A2 induces pulmonary